China, People's Republic of INTRODUCTION AND OBJECTIVES: Sphingosine kinase 1 (SphK1) is the major source of the bioactive lipid and GPCR (G-proteincoupledreceptor) agonist sphingosine 1-phosphate (S1P). Numerous studies have documented that SphK1-S1P signalling hasmultiple functions in tumorigenesis. The present study was conducted to investigate the expression of SphK1-S1P signalling and itsprognostic significance in renal cell carcinoma (RCC). Meanwhile, we set out to SphK1 as a novel molecular target in RCC andexamine its role in tumor cell growth and sunitinib resistance in vitro and in vivo.
INTRODUCTION AND OBJECTIVES: Sphingosine kinase 1 (SphK1) is the major source of the bioactive lipid and GPCR (G-proteincoupledreceptor) agonist sphingosine 1-phosphate (S1P). Numerous studies have documented that SphK1-S1P signalling hasmultiple functions in tumorigenesis. The present study was conducted to investigate the expression of SphK1-S1P signalling and itsprognostic significance in renal cell carcinoma (RCC). Meanwhile, we set out to SphK1 as a novel molecular target in RCC andexamine its role in tumor cell growth and sunitinib resistance in vitro and in vivo.
METHODS: In this study, SphK1 expression levels as well as clinicopathological significance were evaluated in RCCcell lines and primary RCC clinical specimens by immunohistochemistry, immunofluorescence assay, qRT-PCR and western blot. We assessed the levels of S1P and Sph in tumor tissues by HPLC analysis and in the plasma of RCC patients and healthy controls byLC-MS/MS analysis. In vitro and in vivo knockdown or overexpression of SphK1 in RCC cell lines was used to determine its effecton tumor growth, cellular proliferation, colony formation, migration, invasion, and apoptosis. We conducted a phosphoproteinantibody array to identify ectopic phosphorylated proteins induced in 786-O cells with/without SphK1 expression vector. In addition,we further evaluated the effect of SphK1 antagonist fingolimod (FTY720) in RCC in vitro and in vivo, as a single agent or incombination with sunitinib, and attempted to explore its anticarcinogenic mechanisms.
RESULTS: We identify upregulation of SphK1 significantly associated with poor prognosis of RCC patients, which contributing torenal proliferation, colony formation, migration and survival. Suppression of SphK1 activity either by shRNA or pharmacologicinhibitior FTY720 suppresses cell growth in vitro and in vivo. A comprehensive phosphoprotein antibody array reveals that SphK1overexpression promoted RCC progression by regulating the Akt/mTOR pathway. SphK1 could act as a canonical regulator ofhypoxia-inducible HIF-1a and HIF2a in RCC cells. Moreover, stem-like phenotype due to sunitinib administration via oncogenicactivation of SphK1 could be ameliorated by SphK1 shRNA and FTY720. FTY720 administration enhanced tumor growth inhibitioneffect of sunitinib treatment on RCC cells in vitro and in vivo.
CONCLUSIONS: Our results unraveled that increased SphK1 kinase activation defines an important mechanism for maintaining stemlikephenotype and sunitinib resistance, therefore contributes to tumour development and represents therapeutic targets for RCC.
Source of Funding: NONE

MP72-02 METABOLISM RE-PROGRAMMING AS A THERAPEUTIC TARGET FOR DRUG RESISTANT RENAL CELL CARCINOMA
Hirofumi Yoshino*, Kazutaka Miyamoto, Masaya Yonemori, Satoru Sugita, Takashi Sakaguchi, Hideki Enokida, Masayuki Nakagawa, Kagoshima, Japan INTRODUCTION AND OBJECTIVES: It has been revealed that metabolism re-programming, such as Warburg effect, occurs in cancer cells. Recently, it was reported that anti-tumor effects of a HIF2a antagonist was greatly exceeded that of sunitinib in renal cell carcinoma (RCC) (Nature, 2016). However, drug-resistant acquisition will be a future problem. In this study, we aimed to elucidate the mechanism and conquest of drug resistant acquisition regarding HIF2a based on metabolism re-programming.
METHODS: First, we established a sunitinib-resistant RCC cell line (SU-R-786-o) in vivo by oral gavage treatment, followed by the establishment of HIF2a knockout cell line (HIF2a-KO-SU-R-786-o) by CRISPR/Cas9. We performed omics analyses using these cells. By using new inhibitors of phosphoglycerate dehydrogenase (PHGDH), which was selected as a candidate gene for drug resistance by omics analyses, we performed proliferation and apoptosis assay in vitro, and a xenograft assay. PHGDH-overexpressed cells by lentiviral vector were subjected to a colony formation assay. We also performed statistical analyses based on TCGA database of RCC patients.
RESULTS: SU-R-786-o showed significant sunitinib resistance both in vitro and in vivo. The expression of known HIF2a target genes was markedly suppressed in HIF2a-KO-SU-R-786-o. HIF2a-KO-SU-R-786-o significantly reduced cell proliferation compared to control cells, but it still survived, probably due to accelerated alternative pathways. Metabolomics analysis showed that metabolites were clearly divided among 786-o, SU-R-786-o, and HIF2a-KO-SU-R-786-o, and that serine biosynthesis was significantly activated in HIF2a-KO-SU-R-786-o. In addition, RNA sequence and quantitative proteome analyses showed that PHGDH, a key enzyme for serine synthesis, was accelerated in HIF2a-KO-SU-R-786-o. PHGDH inhibitor reduced cell growth in vivo and in vitro by inducing apoptosis in HIF2a-KO-SU-R-786-o more than in parent cells. Whereas, PHGDH overexpressed cells exhibited a significant increase in colony numbers compared to parent cells. TCGA database showed that patients with PHGDH gene amplification (n ¼ 24) had poor overall survival (P ¼ 0.0003) compared to patients without amplification (n ¼ 500).
CONCLUSIONS: Metabolism re-programming occurred in drug-resistant RCCs. In addition, PHGDH can be a therapeutic target for patients showing activated serine biosynthesis after HIF2a deficiency. Furthermore, PHGDH inhibitor should be considered as a first treatment in patients with PHGDH amplification.
Source of Funding: none
MP72-03 SORAFENIB-TRIGGERED STRESS GRANULES PROMOTE RESISTANCE IN RENAL CANCER CELLS BY RECRUITING ANTI-APOPTOTIC CYCLOOXYGENASE 2
Wei Chen*, Xiaozhi Zhao, Wenmin Cao, Wenli Diao, Hongqian Guo, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: A significant proportion of RCC patients are inherently refractory to sorafenib, and most of the remaining patients develop resistance. The stress granules (SGs) induced by sorafenib contributing to renal cancer cells resistance is unknown.
METHODS: In ACHN and 786O cells, SGs were shown by immunofluorescence using canonical SGs markers HuR, TIA-1 and G3BP1. The activation of GCN2 and the phosphorylation of its downstream eIF2a were detected by western blotting. Cells apoptosis percentages were measured by AnnexinV-PI staining. Cox2 mRNA level was evaluated by real-time quantitative polymerase chain reaction (RTqPCR). RNA-FISH was performed using specific Cox2 mRNA probes.
RESULTS: We found that sorafenib can trigger the formation of many small cytoplasmic foci in renal cancer cells. These particles-like foci were characterized as stress granules (SGs), because they were nicely co-localized with SG markers HuR, TIA-1 and G3BP1 (Fig.1A,  1B) . These SGs have a protective role. The SGs triggered by sorafenib were found to be dependent on GCN2-eIF2a signaling. Sorafenib increased the phosphorylation of General control nonderepressible kinase 2 (GCN2) and its downstream eIF2a without influencing the total protein. Silencing of GCN2 expression also promoted sorafenibe952 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 
